Medical device manufacturers making cosmetic / aesthetic products.
The FTC issued a "Second Request" for more information about Valeant Pharmaceuticals' ongoing attempts to take over Allergan.
Federal authorities are taking a closer look at Allergan's (NYSE:AGN) ongoing battle to keep unrequited acquirer Valeant Pharmaceuticals at bay.
Allergan uses the occasion of unrequited buyer Valeant Pharmaceuticals' latest financial report to drive home allegations that Valeant isn't being upfront about its business and accounting practices.
Aesthetics devices maker Ulthera withdraws its $86 million initial public offering after agreeing to an acquisition by Merz that's valued at up to $600 million.
Arizona device maker Ulthera is ditching its planned initial public offering in favor of a $600 million merger with larger aesthetics company Merz Inc., according to an SEC filing.
Botox-maker Allergan announces restructuring measures that will cut 13% of its global workforce as the company sinks deeper into a months-long battle against activist investors and attempts at a takeover.
Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan's earnings.
Activist investor Bill Ackman urges shareholders to take action before time runs out on Valeant Pharmaceuticals' hostile $53 billion bid to acquire Allergan.
Another hedge fund buys a massive stake in Botox-maker Allergan, throwing its support behind Valeant Pharmaceuticals' unrequited acquisition bid, according to a report.
Another player entered the arena in the running saga over Allergan (NYSE:AGN) as hedge fund Paulson & Co bought up a huge chunk of the Botox-maker's shares, according to Reuters.
Valeant Pharmaceuticals makes its promised hostile play in a $53 billion attempt to take over Botox-maker Allergan.
Valeant Pharmaceuticals is preparing to officially launch its long-promised hostile takeover bid for Allergan (NYSE:AGN), aiming to solicit support from Allergan shareholders to host a special meeting outside of the company's control.